Chief Editor Louis Garguilo at Outsourced Pharma speaks with VP of Industry Standard Research Kate Hammeke about the non-appearance of a long-anticipated capacity crunch for bioprocessing services.
One thing is certain: When considering overall outsourcing capacity, there are mitigating factors at work in the marketplace. The most important is that the bigger drug sponsors have in fact built out (and continue to do so) their own internal capacity. And biomanufacturing is complicated: The business model of choice – keeping bioprocesses and manufacturing internal – may be winning the day.
Read more at Outsourced Pharma, and learn more about our report Bioprocessing Market Trends & Outsourcing Dynamics: 2018-2023 (2nd Edition).
